The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by David A. Ehrmann and Robert Rosenfield.
Connection Strength

3.353
  1. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016 10; 37(5):467-520.
    View in: PubMed
    Score: 0.563
  2. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012 Jul; 98(1):242-9.
    View in: PubMed
    Score: 0.419
  3. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod. 2011 Nov; 26(11):3138-46.
    View in: PubMed
    Score: 0.402
  4. Letter to the Editor From Rosenfield, et al: "Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome". J Clin Endocrinol Metab. 2024 Sep 16; 109(10):e1962-e1963.
    View in: PubMed
    Score: 0.248
  5. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 04 01; 103(4):1233-1257.
    View in: PubMed
    Score: 0.158
  6. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 1995 Jun; 16(3):322-53.
    View in: PubMed
    Score: 0.130
  7. Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood. J Clin Endocrinol Metab. 2015 Apr; 100(4):1537-43.
    View in: PubMed
    Score: 0.127
  8. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1994 Dec; 79(6):1686-92.
    View in: PubMed
    Score: 0.126
  9. Gonadotropin-releasing hormone agonist testing of pituitary-gonadal function. Trends Endocrinol Metab. 1991 May-Jun; 2(3):86-91.
    View in: PubMed
    Score: 0.098
  10. Hirsutism--beyond the steroidogenic block. N Engl J Med. 1990 Sep 27; 323(13):909-11.
    View in: PubMed
    Score: 0.094
  11. Clinical review 10: An endocrinologic approach to the patient with hirsutism. J Clin Endocrinol Metab. 1990 Jul; 71(1):1-4.
    View in: PubMed
    Score: 0.092
  12. Potential diagnostic utility of intermittent administration of short-acting gonadotropin-releasing hormone agonist in gonadotropin deficiency. Fertil Steril. 2010 Dec; 94(7):2697-702.
    View in: PubMed
    Score: 0.092
  13. Use of nafarelin for testing pituitary-ovarian function. J Reprod Med. 1989 Dec; 34(12 Suppl):1044-50.
    View in: PubMed
    Score: 0.089
  14. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab. 2009 May; 94(5):1587-94.
    View in: PubMed
    Score: 0.084
  15. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab. 2009 May; 94(5):1579-86.
    View in: PubMed
    Score: 0.084
  16. Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):270-6.
    View in: PubMed
    Score: 0.067
  17. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab. 2003 Dec; 88(12):6115; author reply 6115-6.
    View in: PubMed
    Score: 0.059
  18. Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab. 2000; 13 Suppl 5:1285-9.
    View in: PubMed
    Score: 0.045
  19. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999 Jan; 22(1):141-6.
    View in: PubMed
    Score: 0.042
  20. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Jul; 82(7):2108-16.
    View in: PubMed
    Score: 0.038
  21. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb; 82(2):524-30.
    View in: PubMed
    Score: 0.036
  22. Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin--a clinical research center study. J Clin Endocrinol Metab. 1996 Sep; 81(9):3408-11.
    View in: PubMed
    Score: 0.035
  23. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995 Jul; 96(1):520-7.
    View in: PubMed
    Score: 0.033
  24. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. Ann N Y Acad Sci. 1993 May 28; 687:162-81.
    View in: PubMed
    Score: 0.028
  25. Ovarian steroidogenic responses to gonadotropin-releasing hormone agonist testing with nafarelin in hirsute women with adrenal responses to adrenocorticotropin suggestive of 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency. J Clin Endocrinol Metab. 1993 Feb; 76(2):450-5.
    View in: PubMed
    Score: 0.028
  26. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 1992 Jul 16; 327(3):157-62.
    View in: PubMed
    Score: 0.027
  27. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab. 2012 Jul; 97(7):E1342-7.
    View in: PubMed
    Score: 0.026
  28. A new test of combined pituitary-testicular function using the gonadotropin-releasing hormone agonist nafarelin in the differentiation of gonadotropin deficiency from delayed puberty: pilot studies. J Clin Endocrinol Metab. 1989 Nov; 69(5):963-7.
    View in: PubMed
    Score: 0.022
  29. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 1989 Mar 02; 320(9):559-65.
    View in: PubMed
    Score: 0.021
  30. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008 Apr; 93(4):1105-20.
    View in: PubMed
    Score: 0.020
  31. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994 Nov; 79(5):1328-33.
    View in: PubMed
    Score: 0.008
  32. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1993 May; 76(5):1241-7.
    View in: PubMed
    Score: 0.007
  33. Maturation of gonadotropin and sex steroid responses to gonadotropin-releasing hormone agonist in males. J Clin Endocrinol Metab. 1993 Feb; 76(2):362-6.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.